Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March
BAAR, Switzerland --(BUSINESS WIRE)--Apr. 1, 2026-- Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m.
BAAR, Switzerland --(BUSINESS WIRE)--Mar. 26, 2026-- Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq ®), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line
Novocure to launch Optune Lua in Japan with national reimbursement coverage BAAR, Switzerland --(BUSINESS WIRE)--Mar. 2, 2026-- Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua ® through the country’s National Health